New hVIVO contract signed with a European Biotech Company

Initial study for the provision of a RSV human challenge study Respiratory Syncytial Virus (“RSV”) human challenge study Projected to deliver £3.2m in revenue in 2020 with the pivotal challenge study expected to commence end Q4 2020, with the potential to deliver significant further revenue expected to be a […]

Click here to view original web page at